公开(公告)号：EP1362600B1

公开(公告)日：2008-04-02

申请号：EP02711351.3

申请日：2002-02-06

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KANEDA, Yasufumi, c/o AnGes MG, Inc. ,  NAKAMURA, Hiroshige

IPC分类号： A61K48/00 ,  A61K31/711 ,  A61K9/06 ,  A61K47/06 ,  A61K47/10 ,  A61P17/00 ,  A61P17/04

CPC分类号： A61K31/711 ,  A61K38/1709 ,  C12N15/113 ,  C12N2310/13

公开(公告)号：EP1470826B1

公开(公告)日：2009-01-28

申请号：EP02711288.7

申请日：2002-02-01

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KAWASAKI, Tomio, c/o AnGes MG, Inc.

IPC分类号： A61K48/00 ,  A61K31/711 ,  A61P9/10 ,  A61K9/08 ,  A61P29/00 ,  A61P11/06 ,  A61P17/00 ,  A61P13/12

CPC分类号： A61K9/127 ,  A61K31/711 ,  A61K38/08 ,  A61K38/1709 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  A61K48/0008 ,  A61K48/005 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/13 ,  C12N2710/10343 ,  C12N2740/13043

摘要： Pharmaceutical compositions for treating and preventing diseases caused by the expression of a gene under the regulation by NF - ĸB or ets which contain at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy as described above involves a decoy of NF - ĸB, a decoy of ets and a chimeric decoy of a decoy of NF - ĸB and ets. The diseases as described above include brain aneurysm, caner, Marfan’s syndrome, aortic dissection, postangioplastic reconstriction, rheumatoid arthritis, asthma, atopic dermatitis, nephritis, renal insufficiency and plaque rapture. The pharmaceutically acceptable carrier as described above may be a hydrophilic polymer.

公开(公告)号：EP1642591A1

公开(公告)日：2006-04-05

申请号：EP04747306.1

申请日：2004-07-09

申请人： AnGes MG, Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KAWASAKI, Tomio, c/o AnGes MG, Inc. ,  MAKINO, Hirofumi, c/o AnGes MG, Inc., ,  SHISHIKURA, Takashi, c/o Meiji Seika Kaisha, Ltd. ,  KOYANAGI, Akihiro, c/o Meiji Seika Kaisha, Ltd.

IPC分类号： A61K45/00 ,  A61K48/00 ,  A61K31/7088 ,  A61K9/08 ,  A61K9/12 ,  A61K9/127 ,  A61K9/14 ,  A61K9/72 ,  A61K47/10 ,  A61K47/26 ,  A61K47/30 ,  A61K35/76 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06

CPC分类号： A61K9/0078 ,  A61K9/0075 ,  A61K9/008 ,  A61K31/711 ,  A61K38/1709 ,  A61K45/06

摘要： A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by an eosinophil abnormality (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.

摘要翻译： 用于治疗和预防疾病，病症和/或通过NF-κB的调节的基因，其包含NF-κB的诱饵和药学上可接受的载体的表达引起的气道炎症，气道狭窄或鼻腔炎症的条件的药物组合物。 上述疾病可以是哮喘，COPD或鼻炎。 更完了，上述疾病可以是由嗜酸性粒细胞的异常引起的疾病（例如，哮喘，鼻炎和慢性阻塞性肺病）。 药学上可接受的载体可以是亲水性聚合物，脂质体等。

公开(公告)号：EP1470826A1

公开(公告)日：2004-10-27

申请号：EP02711288.7

申请日：2002-02-01

申请人： Anges MG Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KAWASAKI, Tomio, c/o AnGes MG, Inc.

IPC分类号： A61K48/00 ,  A61K31/711 ,  A61P9/10 ,  A61K35/00 ,  A61K9/00 ,  A61K9/08 ,  A61P29/00 ,  A61P19/02 ,  A61P11/06 ,  A61P17/00 ,  A61P13/12

CPC分类号： A61K9/127 ,  A61K31/711 ,  A61K38/08 ,  A61K38/1709 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  A61K48/0008 ,  A61K48/005 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/13 ,  C12N2710/10343 ,  C12N2740/13043

摘要： A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

公开(公告)号：EP1362600A1

公开(公告)日：2003-11-19

申请号：EP02711351.3

申请日：2002-02-06

申请人： Anges MG Inc.

发明人： MORISHITA, Ryuichi, c/o AnGes MG, Inc. ,  AOKI, Motokuni, c/o AnGes MG, Inc. ,  OGIHARA, Toshio, c/o AnGes MG, Inc. ,  KANEDA, Yasufumi, c/o AnGes MG, Inc. ,  NAKAMURA, Hiroshige, c/o AnGes MG, Inc.

IPC分类号： A61K48/00 ,  A61K31/711 ,  A61K9/06 ,  A61K47/06 ,  A61K47/10 ,  A61P17/00 ,  A61P17/04

CPC分类号： A61K31/711 ,  A61K38/1709 ,  C12N15/113 ,  C12N2310/13

摘要： A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-κB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, or Crohn's disease.

摘要翻译： 一种用于对皮肤病进行治疗的药物组合物，所述药物组合物包含至少一种诱饵和药学上可接受的载体。 至少一个诱饵可以选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵，STAT-6诱饵，AP-1诱饵和Ets诱饵。 所述至少一个诱饵可以是包含至少两个彼此键合的诱饵的寡核苷酸，所述至少两个诱饵选自NF-κB诱饵，STAT-1诱饵，GATA-3诱饵， STAT-6诱饵，AP-1诱饵和Ets诱饵。 皮肤病可能是特应性皮炎，寻常型牛皮癣，接触性皮炎，瘢痕疙瘩，褥疮，溃疡性结肠炎或克罗恩病。